Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation:  selective serotonin reuptake inhibitor response pharmacogenomics.

doi:10.1097/FPC.0b013e32835001c9

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics.

Pharmacogenetics and genomics - 1 Apr 2012

Abo Ryan, Hebbring Scott, Ji Yuan, Zhu Hongjie, Zeng Zhao-Bang, Batzler Anthony, Jenkins Gregory D, Biernacka Joanna, Snyder Karen, Drews Maureen, Fiehn Oliver, Fridley Brooke, Schaid Daniel, Kamatani Naoyuki, Nakamura Yusuke, Kubo Michiaki, Mushiroda Taisei, Kaddurah-Daouk Rima, Mrazek David A, Weinshilboum Richard M

Abstract excerpt

OBJECTIVE: We set out to test the hypothesis that pharmacometabolomic data could be efficiently merged with pharmacogenomic data by single-nucleotide polymorphism (SNP) imputation of metabolomic-derived pathway data on a 'scaffolding' of genome-wide association (GWAS) SNP data to broaden and accelerate 'pharmacometabolomics-informed pharmacogenomic' studies by eliminating the need for initial genotyping and by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Citalopram

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Depressive Disorder

Share to Glycine

Share to HapMap Project

Share to Metabolic Networks and Pathways

Share to Metabolomics

Share to Pharmacogenetics

Share to Selective Serotonin Reuptake Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 22322242
DOI: 10.1097/FPC.0b013e32835001c9
PMCID: PMC3303952

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics.PMID 22322242Read ↗

Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.Semantic proximity Read ↗

Genetic Epidemiological Pipeline Identifies Candidate Markers of Clozapine-Induced Metabolic Dysfunction Revealing Potential Avenues for Precision Clozapine PrescriptionSemantic proximity Read ↗

Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine MetabolismSemantic proximity Read ↗

TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics.Semantic proximity Read ↗

New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation.Semantic proximity Read ↗

Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort.Semantic proximity Read ↗

Genome-wide association study of monoamine metabolite levels in human cerebrospinal fluid.Semantic proximity Read ↗

Recent development in pharmacogenomics: from candidate genes to genome-wide association studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.